MAP3K5 and metabolic dysfunction-associated steatohepatitis: Thus, Lys6-linked polyubiquitination of ASK1 by TRAF6 represents a novel mechanism of ASK1 activation in hepatocytes, and could be a potential target for NASH therapy.